tiprankstipranks
pc:par1v

Parabilis Medicines

Parabilis Medicines is a clinical-stage biopharmaceutical company developing a new class of stabilized, cell-penetrant alpha-helical peptides called Helicons to target intracellular proteins that have historically been considered undruggable. The company is advancing a focused oncology pipeline, including FOG-001 (zolucatetide), a direct inhibitor of the β-catenin:TCF interaction, and programs targeting prostate cancer and other Wnt/β-catenin-driven tumors.

Leadership & Board

Currently, no data available

Latest Estimated Valuation

Estimated Valuation
Estimated Valuation
Total Amount Raised$305M
Total Amount Raised$305M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$305M
Latest Funding Amount$305M
Latest Funding RoundSeries F
Latest Funding RoundSeries F
Post-Money Valuation
Post-Money Valuation

Funding Round

Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Jan 08, 2026
Series F
$305.00M

Related News and Analysis